Uterine Motility Patents (Class 514/935)
-
Patent number: 6664290Abstract: This invention relates to a method of limiting postpartum hemorrhage comprising administering orally a single effective dose of misoprostol to a woman during the third stage of labor.Type: GrantFiled: April 15, 1997Date of Patent: December 16, 2003Assignee: University College LondonInventor: Hazem El-Rafaey
-
Patent number: 6586021Abstract: The invention discloses a process of extracting, fractionating and purifying bioactive molecules from an associated mangrove plant, methods of screening for pharmacological activities of the crude extract, fractions, and purified compounds.Type: GrantFiled: May 13, 2002Date of Patent: July 1, 2003Assignee: Council of Scientific & Industrial ResearchInventors: Usha Goswami, Nazarine Fernandes
-
Patent number: 6428823Abstract: The invention discloses a process of extracting, fractionating and purifying bioactive molecules from an associated mangrove plant, methods of screening for pharmacological activities of crude extract, it fractions and purified compounds and the use of the aqueous fraction of the crude extract as a tocolytic agent.Type: GrantFiled: March 28, 2001Date of Patent: August 6, 2002Assignee: Council of Scientific & Industrial ResearchInventors: Usha Goswami, Nazarine Fernandes
-
Patent number: 6306899Abstract: This invention relates to anti-viral drugs such as Helioxanthin and its analogs. The present compounds may be used alone or in combination with other drugs for the treatment of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses. In addition, compounds according to the present invention can be used to prevent hepatoma secondary to virus infection as well as other infections or disease states which are secondary to the virus infection.Type: GrantFiled: August 23, 1999Date of Patent: October 23, 2001Assignees: Yale University, N. Y. Mu, N.T.U., V.G.HInventors: Yung-Chi Cheng, Chen-Kung Chou, Lei Fu, Yueh-Hsiung Kuo, Sheau-Farn Yeh, Juliang Zhu, Yonglian Zhu
-
Patent number: 6271201Abstract: Methods for inhibiting the production of specific vasoconstrictive prostanoids, such as thromboxane and prostaglandin F2&agr;, through the addition of insulin like growth factor, particularly IGF-I or IGF-II, to human placental cells are disclosed. IGF-I is demonstrated to avoid affecting material and placental production of prostaglandin E, human chorionic gonadotropin, PGFM, and 6-keto-PGF1-alpha by placental cells. Improved methods for vasoregulation of vasoconstrictive diseases of pregnancy are also disclosed. Methods for treating hypertension with IGF-I are also described. Improved methods for inhibiting pre-term labor are also provided. Methods for inducing labor with agents that specifically inhibit insulin like growth factor are also disclosed. Such inhibitors of IGF-I include antibodies, antagonists of IGF-I, and metabolizing enzymes of IGF-I.Type: GrantFiled: July 15, 1993Date of Patent: August 7, 2001Assignee: Board of Regents, The University of Texas SystemInventor: Theresa M. Siler-Khodr
-
Patent number: 6162833Abstract: Aqueous solution, including at least one of optically active (-)-(R)-.alpha.-((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol represented by the following formula: ##STR1## and pharmacologically acceptable salt thereof. The aqueous solution also includes at least one photostabilizer selected from the group consisting of saccharide, sugar alcohol, and polyalcohol. A content of the at least one of optically active (-)-(R)-.alpha.-((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol and pharmacologically acceptable salt thereof is 0.01 to 10% (w/v) based on a volume of the aqueous solution. A content of the at least one photostabilizer is 1 to 50% (w/v) based on the volume of the aqueous solution. The content of the at least one photostabilizer is at least 10% (w/w) based on a total weight of the at least one of optically active (-)-(R)-.alpha.-((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol and pharmacologically acceptable salt thereof. Method of making a stabilized aqueous solution.Type: GrantFiled: April 16, 1999Date of Patent: December 19, 2000Assignee: Hokuriku Seiyaku Co., Ltd.Inventors: Yasuo Ito, Hideo Kato, Eiichi Koshinaka, Masahiro Yamazaki, Kazuya Matsuo
-
Patent number: 5952387Abstract: Aqueous solution, including at least one of optically active (-)-(R)-.alpha.-((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol represented by the following formula: ##STR1## and pharmacologically acceptable salt thereof. The aqueous solution also includes at least one photostabilizer selected from the group consisting of saccharide, sugar alcohol, and polyalcohol. A content of the at least one of optically active (-)-(R)-.alpha.-((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol and pharmacologically acceptable salt thereof is 0.01 to 10% (w/v) based on a volume of the aqueous solution. A content of the at least one photostabilizer is 1 to 50% (w/v) based on the volume of the aqueous solution. The content of the at least one photostabilizer is at least 10% (w/w) based on a total weight of the at least one of optically active (-)-(R)-.alpha.-((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol and pharmacologically acceptable salt thereof. Method of making a stabilized aqueous solution.Type: GrantFiled: January 27, 1998Date of Patent: September 14, 1999Assignee: Hokuriku Seiyaku Co., Ltd.Inventors: Yasuo Ito, Hideo Kato, Eiichi Koshinaka, Masahiro Yamazaki, Kazuya Matsuo
-
Patent number: 5744464Abstract: Antigestagens inhibit prostaglandin synthesis by the uterus and thus can be used to treat symptoms of dysmennhorea.Type: GrantFiled: July 26, 1993Date of Patent: April 28, 1998Assignee: Schering AktiengesellschaftInventors: Walter Elger, Krzysztof Chwalisz, Sybille Beier, Marianne Fahnrich
-
Patent number: 5708036Abstract: The optically pure R-isomer of the adrenergic beta-2 agonist albuterol, substantially free of its corresponding S-isomer, has been found to potently inhibit premature uterine contractions in female subjects, suffering from said condition, while avoiding side effects associated with the corresponding S-isomer. A new method is disclosed utilizing the optically pure R(-)-isomer of albuterol for treating premature uterine contractions while minimizing the side effects associated with administration of racemic albuterol.Type: GrantFiled: January 29, 1996Date of Patent: January 13, 1998Inventor: E. Charles Pesterfield, Jr.
-
Patent number: 5595980Abstract: Improved contraceptive compositions are disclosed which comprise a spermicide or virucide, a polymeric delivery component and optionally a cosmetic ingredient. The improvement is directed to the use of certain hydrophobically modified polysaccharides as the polymeric delivery component. Quite advantageously, the hydrophobically modified polysaccharides of the present invention can alter sperm motility. Moreover, the hydrophobically modified polysaccharides can provide reduced irritation potential when used in combination with spermicides such as, for example, nonoxynol-9, which may reduce the potential for infection of sexually transmitted diseases such as HIV and herpes.Type: GrantFiled: April 7, 1995Date of Patent: January 21, 1997Assignees: Medical College of Hampton Roads, Biomaterials CorporationInventors: George L. Brode, Gustavo F. Doncel, Henry L. Gabelnick, Russell L. Kreeger, George A. Salensky
-
Patent number: 5529993Abstract: A 14.alpha.,17.alpha.-bridged estratriene of formula I ##STR1## wherein (a) OR.sup.3 is in .alpha.-positionR.sup.1, R.sup.2 and R.sup.3, each independently are (i) hydrogen, (ii) ##STR2## in which R.sup.4 is an organic radical with up to 11 carbon atoms or (iii) --(CH.sub.2).sub.n COOH wherein n=1-4, or (iv) R.sup.1 is a benzyl, C.sub.1 -C.sub.8 alkyl or C.sub.3 -C.sub.5 cycloalkyl, or(b) OR.sup.3 is in .beta.-positionR.sup.1, R.sup.2 and R.sup.3, each independently are (i) hydrogen, (ii) an acyl group with 1 to 12 carbon atoms or (iii) R.sup.1 is C.sub.1 -C.sub.8 alkyl, and in both (a) and (b) A--B is an etheno or ethano bridge.Type: GrantFiled: November 29, 1990Date of Patent: June 25, 1996Assignee: Schering AktiengesellschaftInventors: Gerald Kirsch, Gunter Neef, Henry Laurent, Rudolf Wiechert, James Bull, Peter Esperling, Walter Elger, Sybille Beier
-
Patent number: 5518716Abstract: A microemulsion composition comprising a microemulsifiable silicone and a volatile silicone, the microemulsion formed therewith, a means for preparing said microemulsion, and personal care products comprising said microemulsion.Type: GrantFiled: March 31, 1994Date of Patent: May 21, 1996Assignee: General Electric CompanyInventors: Donna A. Riccio, James H. Merrifield
-
Patent number: 5504116Abstract: The use of lidocaine or other Class I cardiac antiarrhythmic compound in the management of preterm labor and the stoppage of labor preparatory to cesarian delivery, is disclosed. The electrophysiological effects of lidocaine on the sodium, calcium and potassium channels of freshly dissociated myocytes from late-pregnant rat uteri with the tight-seal patch-clamp method are presented. Dose-response relations on the sodium and calcium currents, and effects on the availability relation for sodium current are also presented. Also disclosed are the effects of chronic administration of lidocaine on the duration of pregnancy.Type: GrantFiled: May 26, 1994Date of Patent: April 2, 1996Assignee: Research Foundation of State University of New YorkInventors: Chien-Yuan Kao, Shuya Wang
-
Patent number: 5409955Abstract: There is disclosed a composition for inhibiting uterine contractility by topical or local administration. The composition contains an omega fatty acid in combination with a cyclo-oxygenase inhibitor. Preferred omega fatty acids include docosahexaenoic acid and eicosapentaenoic acid, and preferred cyclo-oxygenase inhibitors include acetylsalicylic acid and salicylic acid. The composition may further include pharmaceutically acceptable carriers or diluents, and may be locally applied via intracervical or intrauterine application, or may be topically applied to the skin of the lower abdomen.Type: GrantFiled: May 13, 1993Date of Patent: April 25, 1995Inventors: Barry I. Bockow, Marc D. Erlitz
-
Patent number: 5356904Abstract: A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compounds of the formula ##STR1## wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; R.sup.Type: GrantFiled: October 7, 1992Date of Patent: October 18, 1994Assignee: Merck & Co., Inc.Inventors: Roger M. Freidinger, Joseph M. Pawluczyk, Douglas J. Pettibone, Peter D. Williams
-
Patent number: 5246704Abstract: Disclosed is a vaginal suppository comprising a pharmaceutically acceptable salt of dehydroepiandrosterone sulfate (hereinafter referred to as DHAS), an amino acid and a hard fat having a hydroxy value of not more than 50. This suppository features an improved absorption of the active drug from the vagina plus a good shelf life.Type: GrantFiled: July 14, 1992Date of Patent: September 21, 1993Assignee: Kanebo, Ltd.Inventors: Minoru Sakaguchi, Norio Awata, Tsuneo Kawashima, Hiroshi Nakagawa
-
Patent number: 5198463Abstract: A method for inhibiting oxytocin activity by administering an oxytocin inhibiting amount of a penicillide compound having the formula ##STR1## and compositions for such use are described.Type: GrantFiled: March 30, 1992Date of Patent: March 30, 1993Assignee: Merck & Co., Inc.Inventors: Douglas J. Pettibone, Gino M. Salituro
-
Patent number: 5118673Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.Type: GrantFiled: July 27, 1990Date of Patent: June 2, 1992Assignee: Carrington Laboratories, Inc.Inventors: Robert H. Carpenter, Harley R. McDaniel, Bill H. McAnalley
-
Patent number: 5116619Abstract: A vaginal progesterone suppository is provided in the form of a tablet which delivers biologically effective amounts of progesterone for at least about 48 hours, and blood amounts above basal levels for 72 hours. The tablet is formulated to preferably have a hardness on its edge of 8-13 kg, and disintegrates from its surface to form a milky suspension in 6-8 hours after it is inserted in the vaginal vault. The tablet contains, by weight, about 13-20% progesterone, 65-85% lactose, 2-10% corn starch paste binder, 3-10% corn starch disintegrant, and 0.1-0.9% magnesium stearate as a lubricant. The ratio by weight of progesterone to lactose is preferably 1:6, and the ratio of starch paste binder to starch disintegrant is preferably 1:1. This dosage form is an effective treatment for many progesterone deficiency conditions, and provides enhanced bioavailability.Type: GrantFiled: August 30, 1988Date of Patent: May 26, 1992Assignees: Lee Roy Morgan, John C. GrecoInventors: John C. Greco, James W. McGinity
-
Patent number: 5095010Abstract: Combination products containing an antigestagen, a glucocorticoid and a prostaglandin are suitable for combined use in inducing labor or terminating pregnancy.Type: GrantFiled: November 13, 1990Date of Patent: March 10, 1992Assignee: Schering AktiengesellschaftInventors: Walter Elger, Sybille Beier
-
Patent number: 5036107Abstract: 1-Phenyl-7-substituted-hept-5-yn-2-ones substituted with a C.sub.1 to C.sub.7 alkyl, C.sub.3 to C.sub.6 cycloalkyl, aryl, heteroaryl or heterocycloalkyl group at the 1-position and an amino, a dialkylamino, a piperidyl, a pyrrolidyl or a hexahydroazepinyl group at the 7-position are disclosed which may have one or two substituents in addition to the phenyl group at the 1-position and also may have a p-fluoro substituent on the phenyl group. The preferred compounds are, 1-cyclohexyl-1-phenyl-1-hydroxy-7-dimethylaminohept-5-yn-2-one, 1-cyclobutyl-1-phenyl-1-hydroxy-7-dimethylaminohept-5-yn-2-one and 1-cyclo-1-phenyl-1-hydroxy-7-ethylaminohept-5-yn-2-one.The compounds are highly specific M.sub.1 -AChR antagonists with relatively prolonged duration of activity.Type: GrantFiled: November 16, 1989Date of Patent: July 30, 1991Assignee: Marion Merrell Dow Inc.Inventors: Waclaw J. Rzeszotarski, Maria E. Guzewska, Daniel W. McPherson, Ciro J. Spagnuolo, Kenneth J. Natalie, Jr.
-
Patent number: 5036056Abstract: Methods for treating damaged corneal, uterine or cartilage tissue comprising applying a therapeutically effective amount of a composition comprising:(a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, glycosaminoglycans and glycoproteins wherein said collagens, said proteoglycans, said glycosamino glycans, and said glycoproteins have each been extracted from an extracellular connective tissue matrix and are in their native structural form and(b) a pharmaceutically acceptable carrier.Type: GrantFiled: March 27, 1990Date of Patent: July 30, 1991Inventor: Martin Kludas
-
Patent number: 5011688Abstract: A liquid composition for the relief of premenstrual and menstrual discomfort comprising, as active pharmaceutical agents, an effective amount of an analgesic, an antihistamine, and a diuretic, said active agents being dissolved in a liquid vehicle, said composition containing 5-25 percent by volume alcohol and being flavored with active flavoring elements selected from the group consisting of citrus, vanilla, and mint, said active flavoring ingredients being present in an amount sufficient to mask the unpleasant taste of the pharmaceutically active agents.Type: GrantFiled: May 8, 1990Date of Patent: April 30, 1991Inventors: Henry D. Calam, Hans A. Schaeffer
-
Patent number: 4945082Abstract: The rate of viral dysfunction of subject's immune response in the rate of progression of HIV or like virus from seropositive LAS Pre-ARC ARC frank AIDS is tracked and antiviral therapy based upon dsRNA is initiated and regulated using clinical measurements of the most severe immune deficit as a therapeutic indicator.Type: GrantFiled: March 11, 1988Date of Patent: July 31, 1990Assignee: HEM Research, Inc.Inventor: William A. Carter
-
Patent number: 4870067Abstract: A combination product contains oxytocin and/or an oxytocin analog and an antigestagen for induction of birth.Type: GrantFiled: September 5, 1986Date of Patent: September 26, 1989Assignee: Schering AktiengesellschaftInventors: Krzsysztof Chwalisz, Sybille Beier, Walter Elger, Guenter Neef
-
Patent number: 4795744Abstract: The use of mismatched dsRNA, e.g. Ampligen for the manufacture of compositions for use in the selective activation of a latent natural defense system within human cells, both cells already infected with AIDS virus as well as cells at risk to infection. Specific treatments for various clinical phases of the biological continuous of AIDS virus-related events ranging from subtle, early immunological lesions to advanced disease are described. Prophylaxis or prevention of AIDS virus related events, such as by introduction of mismatched double-stranded RNA into various blood products or biological fluids to be used in man (e.g., blood transfusion) or around man (e.g., dialysis programs) are also described.Type: GrantFiled: August 26, 1986Date of Patent: January 3, 1989Assignee: HEM Research, Inc.Inventor: William A. Carter
-
Patent number: 4789669Abstract: A vaginal suppository comprising a pharmaceutically acceptable salt of dehydroepiandrosterone sulfate and a hard fat with a hydroxyl value not exceeding 50. This vaginal suppository is useful for improving the ante-partum condition of pregnant women and features an extended shelf life.Type: GrantFiled: March 10, 1987Date of Patent: December 6, 1988Assignee: Kanebo, Ltd.Inventors: Isao Sugimoto, Hiroyuki Tsuta
-
Patent number: 4499293Abstract: Prostaglandin (PG.sub.1) derivatives having a 5,6-didehydro feature, for example an enol ether of the formula ##STR1## said derivatives having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.Type: GrantFiled: July 28, 1977Date of Patent: February 12, 1985Assignee: The Upjohn CompanyInventors: Roy A. Johnson, Frank H. Lincoln, John E. Pike